These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1980236)

  • 41. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity.
    Andersson PE; Johansson J; Berne C; Lithell H
    J Hum Hypertens; 1994 Mar; 8(3):219-26. PubMed ID: 8006923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
    Davey MJ
    Am J Med; 1989 Aug; 87(2A):36S-44S. PubMed ID: 2569823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of doxazosin and propranolol administration on lipoprotein lipases in cholesterol-fed rats.
    Jansen H; Baggen RG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S16-20. PubMed ID: 2447435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Alpha-adrenoceptor antagonist (blocker)].
    Shigetomi S
    Nihon Rinsho; 1997 Aug; 55(8):2055-60. PubMed ID: 9284423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid metabolism: implications of alpha 1-blockade.
    Rosenthal J
    J Clin Pharmacol; 1993 Sep; 33(9):883-7. PubMed ID: 7901243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alpha-1 blockers. A new generation of antihypertensive agents.
    Humphreys JE; Waite MA
    J Clin Pharm Ther; 1989 Aug; 14(4):263-83. PubMed ID: 2571616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adrenergic mechanisms in the control of plasma lipids in man.
    Day JL; Metcalfe J; Simpson N; Lowenthal L
    Am J Med; 1984 Feb; 76(2A):94-6. PubMed ID: 6142647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective alpha-1 inhibitors: first- or second-line antihypertensive agents?
    Lund-Johansen P; Hjermann I; Iversen BM; Thaulow E
    Cardiology; 1993; 83(3):150-9. PubMed ID: 7904230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of alpha 1-inhibition on lipid metabolism in the rat.
    Woodside WF; Swindell AC
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S27-34. PubMed ID: 2447438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New findings on the use of specific alpha-1 adrenergic blockers in the treatment of high blood pressure].
    Horký K
    Vnitr Lek; 1991 Jun; 37(6):604-11. PubMed ID: 1680257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha 2-adrenergic receptors and calcium: alpha 2-receptor blockade in vascular smooth muscle as an approach to the treatment of hypertension.
    Lee JY; DeBernardis JF
    Methods Find Exp Clin Pharmacol; 1990 Apr; 12(3):213-25. PubMed ID: 1972206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Changes in lipids and lipoproteins caused by the beta-blocking agents used as antihypertensives].
    Rouffy J; Chanu B; Bakir R; Sauvanet JP
    J Pharmacol; 1983; 14 Suppl 2():183-99. PubMed ID: 6138467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension.
    Louis WJ; Drummer OH; Howes LG
    Clin Exp Hypertens A; 1989; 11(5-6):1075-83. PubMed ID: 2571433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents.
    Graham RM
    Am J Cardiol; 1984 Jan; 53(3):16A-20A. PubMed ID: 6141721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.